Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06465030
  4. Details
NCT06465030 Clinical Trial

Identification of Pattern and Factors Affecting Recurrence in Head and Neck Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma Clinical Trial

Official title:
Identification of Pattern and Factors Affecting Recurrence of Head and Neck Carcinoma After Radical IMRT and VMAT

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06465030
Other study ID # Soh-Med-24-04-017MS
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 15, 2024
Est. completion date June 2025

Study information
Verified date May 2024
Source Sohag University
Contact Reem Gamal, M.B.B.Ch
Phone 01094086660
Email reemgamal4996@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study will evaluate the local experiences in treatment of head and neck carcinoma by retrospectively analyzing the incidence and location of recurrence, and also studying factors affecting this recurrence.

Description:

The investigators will evaluate the local experience in treatment of head and neck SCC by retrospectively analyzing the incidence and location of recurrence, either; local recurrence (LR), regional recurrence (RR), or distant mets in eligible head and neck cancer patients treated with IMRT and VMAT in the period from 2018 till 2022 to allow a follow-up for at least 1 year.

Recruitment information / eligibility
Status Recruiting
Enrollment 35
Est. completion date June 2025
Est. primary completion date April 2025
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults aged more than 18 years. Patients with primary non nasopharyngeal head and neck squamous cell carcinoma. Patients who were intended to receive radical treatment delivered by IMRT and VMAT techniques. Exclusion Criteria: - Adults who had double malignancies. Metastatic HNSCC cases.

Study Design

Related Conditions & MeSH terms

  • Carcinoma
  • Recurrence
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Squamous Cell Carcinoma of Head and Neck

Locations
Country Name City State
Egypt Sohag Faculty of Medicine Sohag

Sponsors (1)
Lead Sponsor Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary Pattern of relapse in recurrent head and neck squamous cell carcinoma, evident clinically and measured by images "US,CT, MRI and endoscopy". By MRI neck , CT Neck and chest, Abd.Pelvis us. At least obsevation of 1 year FU of the patient
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03468218 - Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Phase 2
Recruiting NCT05945875 - Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer Phase 1
Completed NCT03229278 - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Phase 1
Recruiting NCT05980000 - Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma Phase 2
Active, not recruiting NCT01468896 - Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery Phase 1/Phase 2
Recruiting NCT04862650 - Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Phase 2
Terminated NCT01602315 - A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT05726370 - Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC Phase 2
Terminated NCT03823131 - Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat Phase 2
Terminated NCT03522584 - Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2
Completed NCT03032250 - Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer N/A
Withdrawn NCT04834349 - Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer Phase 2
Completed NCT04220775 - Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer Phase 1/Phase 2
Recruiting NCT06265285 - Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Phase 2
Recruiting NCT05063552 - Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Phase 2/Phase 3
Recruiting NCT04588038 - NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery Phase 1
Withdrawn NCT05359692 - INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT04282109 - Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) Phase 2
Active, not recruiting NCT03521570 - Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer Phase 2
Recruiting NCT05156970 - Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC Phase 2